BioNTech
BNTX
19 hedge funds and large institutions have $286M invested in BioNTech in 2019 Q4 according to their latest regulatory filings, with 19 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
3.5% more ownership
Funds ownership: 0% → 3.5% (+3.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$58.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$51.2M |
| 3 |
Primecap Management
Pasadena,
California
|
+$47.7M |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$10.5M |
| 5 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
+$6.21M |
Top Sellers
BNTX Hedge Fund Activity: Q4 2019 in Review
19 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q4 2019, worth a combined $286M.
Buyers outnumbered sellers: 19 funds opened new BNTX positions and 0 closed out — a net gain of 19 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Artal Group, opening a new position worth an estimated $58.9M.
- 19 institutional investors held BioNTech (BNTX) as of Q4 2019, up from 0 in Q3 2019.
- Funds reported $286M of BioNTech stock for Q4 2019.
- 19 funds opened new BioNTech positions in Q4 2019 and 0 closed out, a net change of +19 holders.
- The largest BioNTech buyer in Q4 2019 was Artal Group, an estimated $58.9M added.
Based on aggregated 13F filings for Q4 2019.